The race is under way to make faster, cheaper and better GLP-1 drugs that will go beyond reducing obesity levels to treating ...

Liraglutide is a peptide that has gained significant attention in scientific research due to its structural similarity to ...

Researchers identified how a brain circuit involving dopamine and GLP-1 receptor impact palatability and hedonic eating.

With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply for ...

Initial reports of increased suicidality in GLP-1 RA users compared with the general population raised concerns about the risk for this rare but serious adverse event, given the rising popularity ...

Kidney transplant recipients with type 2 diabetes prescribed GLP-1 receptor agonists had 31% lower mortality vs. nonusers. GLP-1 receptor agonist use was associated with 49% lower incidence of ...

However, for crude incidence rates there was an increased incidence of suicidality with GLP-1 receptor agonist vs DPP-4 inhibitor use; 3.9 vs 1.8 per 1000 person-years. HealthDay News — Glucagon ...

Data showed no outcome differences based on diabetes status or type of GLP-1 used. The incidence and risk for suicidality and self-harm were low for individuals given glucagon-like peptide-1 ...

Novo Nordisk announced Monday a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the Danish company is currently the leading player. Novo Nordisk said it’s ...

Though it could have lots of use cases in the future, Phytogene's first order of business is synthesizing glucagon-like peptide-1 (GLP-1 ... incorporate any peptide sequence into the plant ...

The $33.8 billion U.S. medical weight loss market more than doubled in value from 2022 to 2024, due to soaring demand for GLP-1 medications. The tide has turned toward a greater focus on medical ...